Cancer Clinical Trials: What Every Radiologist Wants to Know but Is Afraid to Ask

被引：3

作者：

Alessandrino, Francesco ^{[1
]}

Smith, Daniel A. ^{[2
]}

Spierling, Angela ^{[2
]}

Kikano, Elias ^{[2
]}

Somarouthu, Bhanusupriya ^{[3
]}

Tirumani, Sree Harsha ^{[2
]}

Ramaiya, Nikhil H. ^{[2
]}

机构：

[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA

[2] Case Western Reserve Univ, Univ Hosp, Dept Radiol, Cleveland Med Ctr, 11100 Euclid Ave, Cleveland, OH 44106 USA

[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA

来源：

AMERICAN JOURNAL OF ROENTGENOLOGY | 2021年 / 216卷 / 04期

关键词：

adverse events; clinical trial; drug development; oncologic imaging; tumor response criteria; PROGRESSION-FREE SURVIVAL; RESPONSE EVALUATION CRITERIA; PHASE-II; TUMOR RESPONSE; ADAPTIVE DESIGNS; SUCCESS RATES; END-POINTS; ONCOLOGY; RECIST; MULTICENTER;

D O I：

10.2214/AJR.20.22852

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

OBJECTIVE. The purpose of this article is to provide radiologists with a guide to the fundamental principles of oncology clinical trials. The review summarizes the evolution and structure of modern clinical trials with an emphasis on the relevance of clinical trials in the field of oncologic imaging. CONCLUSION. Understanding the structure and clinical relevance of modern clinical trials is beneficial for radiologists in the field of oncologic imaging.

引用

页码：1099 / 1111

页数：13

共 71 条

[1]

[Anonymous], 2007, FED REG, V72FR, P27575

[2]

[Anonymous], 2014, MED IMAGING CLIN TRI

[3]

[Anonymous], 2018, CLIN TRIAL IM ENDP P

[4] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[5] Twenty-five years of confirmatory adaptive designs: opportunities and pitfalls [J].

Bauer, Peter ;

Bretz, Frank ;

Dragalin, Vladimir ;

Koenig, Franz ;

Wassmer, Gernot .

STATISTICS IN MEDICINE, 2016, 35 (03) :325-347

[6] Discrepancies of assessments in a RECIST 1.1 phase II clinical trial - association between adjudication rate and variability in images and tumors selection [J].

Beaumont, Hubert ;

Evans, Tracey L. ;

Klifa, Catherine ;

Guermazi, Ali ;

Hong, Sae Rom ;

Chadjaa, Mustapha ;

Monostori, Zsuzsanna .

CANCER IMAGING, 2018, 18

[7] Adaptive clinical trials in oncology [J].

Berry, Donald A. .

NATURE REVIEWS CLINICAL ONCOLOGY, 2012, 9 (04) :199-207

[8] Adaptive Designs for Clinical Trials [J].

Bhatt, Deepak L. ;

Mehta, Cyrus .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (01) :65-74

[9] HISTORY OF CLINICAL TRIALS The Emergence of the Randomized, Controlled Trial [J].

Bothwell, Laura E. ;

Podolsky, Scott H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (06) :501-504

[10] Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development [J].

Burt, T. ;

Yoshida, K. ;

Lappin, G. ;

Vuong, L. ;

John, C. ;

de Wildt, S. N. ;

Sugiyama, Y. ;

Rowland, M. .

CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2016, 9 (02) :74-88

← 1 2 3 4 5 6 7 8 →